MAOA (P21397) variants and mutations
MAOA (also known as P21397) is a human protein-coding gene encoding an amine oxidase [flavin-containing] A protein. It degrades serotonin, norepinephrine, dopamine, and other monoamines at the outer mitochondrial membrane and therefore strongly influences neurotransmitter turnover. Rare loss-of-function variants can cause Brunner syndrome with impulsive behavior and neurodevelopmental abnormalities, while enzyme inhibition is used therapeutically in depression. This analysis covers 534 MAOA variants and mutations. Of these, 93% have computational variant effect predictions. Disease context includes Brunner syndrome, Monoamine oxidase A deficiency, and major depressive disorder. Example MAOA variants include M1I, N3S, and Q4*.
Variant analysis overview
- Gene: MAOA
- Protein: P21397
- UniProt accession: P21397
- Organism: Homo sapiens
- Variants analyzed: 534
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 351 unspecified-consequence records; 4 stop-gained variants; 85 missense variants; 82 synonymous variants; 5 splice-region variants; 5 frameshift variants; 2 substitution
- Prediction scores: 499 variants have prediction scores (93% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Brunner syndrome, Monoamine oxidase A deficiency, major depressive disorder, depressive disorder, hereditary disease, mental disorder, Hypertension, hypertensive disorder, melancholia, autism, Intellectual disability, Drooling.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 3 post-translational modification sites.
- Structural context: 15 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable MAOA variants
Examples include M1I, N3S, Q4*, E5K, E5Q, A7V, S8G, S8N. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs1601921232, ClinGen CA413004063, ClinVar RCV000800325, MetaLR 0.04, MetaSVM -1.09, Uncertain significance, Brunner syndrome
- N3S (p.Asn3Ser), gnomAD rs2033179367, REVEL 0.01, MetaLR 0.02
- Q4* (p.Gln4Ter), gnomAD X-43656351-C-T, CADD 28.20
- E5K (p.Glu5Lys), ExAC rs775694295, TOPMed rs775694295, gnomAD rs775694295, REVEL 0.10, MetaLR 0.02, Uncertain significance
- E5Q (p.Glu5Gln), ExAC rs775694295, TOPMed rs775694295, gnomAD rs775694295, REVEL 0.04, MetaLR 0.02, Uncertain significance, not provided; Brunner syndrome
- A7V (p.Ala7Val), rs2519103578, ClinVar RCV004590733, ClinVar RCV005933647, Uncertain significance, not provided
- S8G (p.Ser8Gly), ExAC rs760422737, gnomAD rs760422737, REVEL 0.01, MetaLR 0.03
- S8N (p.Ser8Asn), gnomAD X-43656364-G-A, REVEL 0.02, MetaLR 0.01
- I9M (p.Ile9Met), TOPMed rs1439692807, gnomAD rs1439692807, REVEL 0.01, MetaLR 0.01
- I9S (p.Ile9Ser), TOPMed rs957678830, gnomAD rs957678830, REVEL 0.01, MetaLR 0.01
- I9I (p.Ile9Ile), rs1439692807, gnomAD X-43656368-C-T, CADD 5.03
- A10T (p.Ala10Thr), gnomAD rs1232710646, REVEL 0.01, MetaLR 0.02
- A10V (p.Ala10Val), gnomAD X-43656370-C-T, REVEL 0.02, MetaLR 0.03
- A10A (p.Ala10Ala), rs1347324620, gnomAD X-43656371-G-A, CADD 8.29
- G11C (p.Gly11Cys), Ensembl rs2033179690, MetaLR 0.03, MetaSVM -1.02
- G11A (p.Gly11Ala), gnomAD X-43656373-G-C, REVEL 0.04, MetaLR 0.02
- G11G (p.Gly11Gly), rs763899599, gnomAD X-43656374-C-T, CADD 15.10
- H12Y (p.His12Tyr), TOPMed rs2033179788, gnomAD rs2033179788, REVEL 0.03, MetaLR 0.03
- H12R (p.His12Arg), gnomAD X-43656376-A-G, REVEL 0.02, MetaLR 0.02
- M13V (p.Met13Val), gnomAD X-43656378-A-G, REVEL 0.02, MetaLR 0.03
- M13R (p.Met13Arg), gnomAD X-43656379-T-G, REVEL 0.07, MetaLR 0.03
- D15E (p.Asp15Glu), rs2033179927, UniProt VAR 036545, TOPMed rs2033179927, REVEL 0.25, MetaLR 0.05, Uncertain significance, in a breast cancer sample
- D15N (p.Asp15Asn), rs1268810174, gnomAD rs1268810174, REVEL 0.19, MetaLR 0.08, Variant assessed as somatic; moderate impact., in a breast cancer sample
- V16I (p.Val16Ile), gnomAD X-43656387-G-A, REVEL 0.12, MetaLR 0.04
- V16V (p.Val16Val), rs1479640416, gnomAD X-43656389-A-T, CADD 10.90
- V17L (p.Val17Leu), NCI-TCGA Cosmic COSV5864, MetaLR 0.02, MetaSVM -1.03, Variant assessed as somatic; moderate impact.
- I19T (p.Ile19Thr), rs2519103647, ClinGen CA413004192, ClinVar RCV003622615, Uncertain significance, Brunner syndrome
- G20E (p.Gly20Glu), NCI-TCGA Cosmic COSV5864, MetaLR 0.82, MetaSVM 0.82, Variant assessed as somatic; moderate impact.
- G20G (p.Gly20Gly), gnomAD X-43656401-A-C, CADD 15.70
- G21G (p.Gly21Gly), gnomAD X-43656404-T-C, AlphaMissense 0.07, MetaLR 0.47
- G22G (p.Gly22Gly), gnomAD X-43656407-C-T, CADD 15.10
- G25G (p.Gly25Gly), rs1006349027, gnomAD X-43683514-A-T, CADD 0.10
- L26I (p.Leu26Ile), gnomAD X-43683515-C-A, REVEL 0.73, MetaLR 0.97
- L26L (p.Leu26Leu), rs1217428322, gnomAD X-43683517-A-G, CADD 0.63
- A29T (p.Ala29Thr), gnomAD X-43683524-G-A, REVEL 0.97, MetaLR 0.99
- A29D (p.Ala29Asp), gnomAD X-43683525-C-A, REVEL 0.98, MetaLR 0.99
- L31R (p.Leu31Arg), gnomAD X-43683531-T-G, REVEL 0.78, MetaLR 0.81
- L31L (p.Leu31Leu), rs771174667, gnomAD X-43683532-C-T, CADD 1.20
- L32M (p.Leu32Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L32S (p.Leu32Ser), rs1131691720, ClinGen CA413004284, ClinVar RCV000493079, Ensembl rs1131691720, AlphaMissense 0.95, MetaLR 0.99, Uncertain significance, not provided
- L32F (p.Leu32Phe), gnomAD X-43683535-G-T, REVEL 0.63, MetaLR 0.97
- T33T (p.Thr33Thr), gnomAD X-43683538-T-A, CADD 0.57
- Y35C (p.Tyr35Cys), gnomAD X-43683543-A-G, REVEL 0.21, MetaLR 0.60
- Y35Y (p.Tyr35Tyr), gnomAD X-43683544-T-C, CADD 2.92
- G36G (p.Gly36Gly), rs757940669, gnomAD X-43683547-C-T, CADD 0.18
- V37I (p.Val37Ile), rs779299641, ClinGen CA10390721, ClinVar RCV001987861, ExAC rs779299641, REVEL 0.14, MetaLR 0.33, Uncertain significance, Brunner syndrome
- V37F (p.Val37Phe), gnomAD X-43683548-G-T, REVEL 0.36, MetaLR 0.59
- S38N (p.Ser38Asn), TOPMed rs1270029287, gnomAD rs1270029287, REVEL 0.15, MetaLR 0.42
- S38S (p.Ser38Ser), rs1018232363, gnomAD X-43683553-T-C, CADD 1.60
- L40V (p.Leu40Val), TOPMed rs1230848293, MetaLR 0.01, MetaSVM -0.97, Uncertain significance, not provided
- R45Q (p.Arg45Gln), ExAC rs745892947, TOPMed rs745892947, gnomAD rs745892947, REVEL 0.92, MetaLR 0.89, Uncertain significance, Brunner syndrome
- R45W (p.Arg45Trp), rs796065312, ClinGen CA204424, ClinVar RCV000190424, ClinVar RCV002293426, REVEL 0.93, MetaLR 0.93, Uncertain significance, not provided; Brunner syndrome
- D46G (p.Asp46Gly), rs201519600, ClinGen CA358062, ClinVar RCV000210598, ClinVar RCV000513424, REVEL 0.86, MetaLR 0.88, Uncertain significance
- D46D (p.Asp46Asp), gnomAD X-43683577-C-T, CADD 2.10
- R47K (p.Arg47Lys), NCI-TCGA Cosmic COSV5864, Variant assessed as somatic; moderate impact.
- G50* (p.Gly50Ter), NCI-TCGA Cosmic COSV5864, Variant assessed as somatic; high impact.
- G50R (p.Gly50Arg), rs2147080866, ClinGen CA413004398, ClinVar RCV001568131, Ensembl rs2147080866, AlphaMissense 0.98, MetaLR 0.78, Uncertain significance, not provided
- R51I (p.Arg51Ile), NCI-TCGA Cosmic COSV1001, Variant assessed as somatic; moderate impact.
- T52T (p.Thr52Thr), gnomAD X-43683595-A-T, CADD 4.63
- Y53H (p.Tyr53His), gnomAD X-43683596-T-C, REVEL 0.21, MetaLR 0.55
- Y53Y (p.Tyr53Tyr), rs780201424, gnomAD X-43683598-T-C, CADD 1.30
- T54N (p.Thr54Asn), NCI-TCGA Cosmic COSV1001, REVEL 0.73, MetaLR 0.88, Variant assessed as somatic; moderate impact.
- T54A (p.Thr54Ala), gnomAD X-43683599-A-G, REVEL 0.90, MetaLR 0.91
- T54T (p.Thr54Thr), gnomAD X-43683601-T-A, CADD 3.32
- I55L (p.Ile55Leu), rs747281025, ClinGen CA413004431, ClinVar RCV003622236, AlphaMissense 0.06, MetaLR 0.33, Uncertain significance, Brunner syndrome
- I55T (p.Ile55Thr), gnomAD rs1162350391, REVEL 0.38, MetaLR 0.63
- I55V (p.Ile55Val), rs747281025, ClinGen CA10390724, ClinVar RCV003510468, ExAC rs747281025, REVEL 0.18, AlphaMissense 0.06, Uncertain significance, Brunner syndrome
- R56S (p.Arg56Ser), gnomAD X-43683607-G-C, REVEL 0.68, MetaLR 0.66
- E58D (p.Glu58Asp), rs572229710, Ensembl rs572229710, REVEL 0.12, MetaLR 0.01, Variant assessed as somatic; moderate impact.
- E58G (p.Glu58Gly), gnomAD rs2033550871, REVEL 0.19, MetaLR 0.02
- E58K (p.Glu58Lys), rs759325782, ClinGen CA10390734, ClinVar RCV001772476, ClinVar RCV006467846, REVEL 0.10, MetaLR 0.01, Uncertain significance, not provided; Brunner syndrome
- E58E (p.Glu58Glu), gnomAD X-43693296-G-A, CADD 0.31
- H59Y (p.His59Tyr), gnomAD X-43693297-C-T, REVEL 0.03, MetaLR 0.02
- D61V (p.Asp61Val), ExAC rs764538239, gnomAD rs764538239, REVEL 0.30, MetaLR 0.59
- D61G (p.Asp61Gly), gnomAD X-43693304-A-G, REVEL 0.28, MetaLR 0.48
- Y62Y (p.Tyr62Tyr), rs180855715, gnomAD X-43693308-C-T, CADD 0.45
- V63A (p.Val63Ala), rs754172029, ClinGen CA10390736, ClinVar RCV003871213, ClinVar RCV004987124, REVEL 0.76, MetaLR 0.79, Uncertain significance, Brunner syndrome; Inborn genetic diseases
- V63I (p.Val63Ile), rs2033551075, ClinGen CA413004498, ClinVar RCV001770827, Ensembl rs2033551075, REVEL 0.48, MetaLR 0.78, Uncertain significance, not provided
- V63L (p.Val63Leu), gnomAD X-43693309-G-T, REVEL 0.65, MetaLR 0.71
- D64Y (p.Asp64Tyr), NCI-TCGA TCGA novel, MetaLR 0.23, MetaSVM -0.37, Variant assessed as somatic; moderate impact.
- Y69Y (p.Tyr69Tyr), gnomAD X-43693329-T-C, CADD 1.57
- V70G (p.Val70Gly), gnomAD X-43693328-ATG-A, CADD 23.20
- G71* (p.Gly71Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- G71V (p.Gly71Val), NCI-TCGA TCGA novel, MetaLR 0.92, MetaSVM 1.06, Variant assessed as somatic; moderate impact.
- G71R (p.Gly71Arg), gnomAD X-43693333-G-A, REVEL 0.95, MetaLR 0.93
- G71G (p.Gly71Gly), gnomAD X-43693335-A-T, CADD 3.37
- T73A (p.Thr73Ala), TOPMed rs2033551173, MetaLR 0.84, MetaSVM 0.79
- Q74Q (p.Gln74Gln), rs757566521, gnomAD X-43693344-A-G, CADD 3.44
- N75N (p.Asn75Asn), gnomAD X-43693347-C-T, CADD 2.99
- L78S (p.Leu78Ser), gnomAD X-43693355-T-C, REVEL 0.90, MetaLR 0.90
- L78L (p.Leu78Leu), rs779434656, gnomAD X-43693356-A-G, CADD 6.82
- R79C (p.Arg79Cys), ExAC rs750916164, TOPMed rs750916164, gnomAD rs750916164, REVEL 0.85, MetaLR 0.88, Uncertain significance, Brunner syndrome
- R79G (p.Arg79Gly), rs750916164, ClinGen CA10390740, ClinVar RCV004416011, ExAC rs750916164, REVEL 0.83, MetaLR 0.83, Uncertain significance, Inborn genetic diseases
- R79H (p.Arg79His), rs1290392482, ClinGen CA413004607, ClinVar RCV002462422, gnomAD rs1290392482, REVEL 0.80, MetaLR 0.89, Uncertain significance, not provided
- K82K (p.Lys82Lys), gnomAD X-43693368-G-A, CADD 7.50
- E83D (p.Glu83Asp), TOPMed rs1468915822, REVEL 0.17, MetaLR 0.03
- G85D (p.Gly85Asp), gnomAD X-43693376-G-A, REVEL 0.40, MetaLR 0.12
- G85G (p.Gly85Gly), rs1601935224, gnomAD X-43693377-C-G, CADD 3.78
- I86L (p.Ile86Leu), ExAC rs780148935, TOPMed rs780148935, gnomAD rs780148935, REVEL 0.04, MetaLR 0.01, Uncertain significance
- I86V (p.Ile86Val), rs780148935, ClinGen CA413004649, ClinVar RCV003223810, ExAC rs780148935, REVEL 0.06, MetaLR 0.01, Uncertain significance, not provided
- E87G (p.Glu87Gly), rs747229681, ClinGen CA10390742, ClinVar RCV000805433, ExAC rs747229681, REVEL 0.23, MetaLR 0.04, Uncertain significance, Brunner syndrome
- E87K (p.Glu87Lys), gnomAD X-43693381-G-A, REVEL 0.06, MetaLR 0.02
- E87E (p.Glu87Glu), rs2033551592, gnomAD X-43693383-G-A, CADD 3.36
- E87D (p.Glu87Asp), gnomAD X-43693383-G-C, REVEL 0.17, MetaLR 0.03
- T88I (p.Thr88Ile), ExAC rs768926368, gnomAD rs768926368, REVEL 0.32, MetaLR 0.10
- T88N (p.Thr88Asn), ExAC rs768926368, gnomAD rs768926368, REVEL 0.31, MetaLR 0.09
- Y89* (p.Tyr89Ter), TOPMed rs913828202, gnomAD rs913828202
- Y89C (p.Tyr89Cys), TOPMed rs2033551680, gnomAD rs2033551680, REVEL 0.86, MetaLR 0.89
- Y89Y (p.Tyr89Tyr), rs913828202, gnomAD X-43693389-C-T, CADD 4.09
- V91V (p.Val91Val), rs781408673, gnomAD X-43693395-G-A, CADD 4.48
- V93I (p.Val93Ile), TOPMed rs1348356432, MetaLR 0.46, MetaSVM -0.55
- S94G (p.Ser94Gly), rs2033551853, ClinGen CA413004702, ClinVar RCV001765305, ClinVar RCV002540366, AlphaMissense 0.08, MetaLR 0.47, Uncertain significance, Inborn genetic diseases; not provided
- S94S (p.Ser94Ser), rs910533865, gnomAD X-43693404-T-C, CADD 3.26
- E95G (p.Glu95Gly), Ensembl rs2147085452, REVEL 0.46, MetaLR 0.41
- E95E (p.Glu95Glu), rs368820082, gnomAD X-43693407-G-A, CADD 3.24
- R96C (p.Arg96Cys), TOPMed rs1316821465, gnomAD rs1316821465, REVEL 0.37, MetaLR 0.66
- R96H (p.Arg96His), ExAC rs769511910, TOPMed rs769511910, gnomAD rs769511910, REVEL 0.38, MetaLR 0.72, Uncertain significance, Brunner syndrome
- R96S (p.Arg96Ser), gnomAD X-43693408-C-A, REVEL 0.33, MetaLR 0.64
- L97P (p.Leu97Pro), rs2147085459, ClinGen CA413004727, ClinVar RCV001952245, Ensembl rs2147085459, AlphaMissense 0.85, MetaLR 0.86, Uncertain significance, Brunner syndrome
- L97L (p.Leu97Leu), rs773175573, gnomAD X-43693413-C-A, CADD 1.54
- V98I (p.Val98Ile), TOPMed rs1465678248, gnomAD rs1465678248, REVEL 0.07, MetaLR 0.01
- V98L (p.Val98Leu), TOPMed rs1465678248, gnomAD rs1465678248, REVEL 0.10, MetaLR 0.03
- Q99Q (p.Gln99Gln), rs979287301, gnomAD X-43693419-A-G, CADD 1.22
- Y100H (p.Tyr100His), TOPMed rs1202580246, gnomAD rs1202580246, REVEL 0.10, MetaLR 0.01, Conflicting interpretations, Brunner syndrome; Inborn genetic diseases
- Y100N (p.Tyr100Asn), NCI-TCGA Cosmic COSV5864, MetaLR 0.06, MetaSVM -1.10, Variant assessed as somatic; moderate impact.
- Y100C (p.Tyr100Cys), gnomAD X-43693421-A-G, REVEL 0.37, MetaLR 0.09
- G103E (p.Gly103Glu), NCI-TCGA Cosmic COSV5864, REVEL 0.69, MetaLR 0.20, Variant assessed as somatic; moderate impact.
- K104K (p.Lys104Lys), gnomAD X-43711877-A-G, CADD 6.83
- T105A (p.Thr105Ala), gnomAD rs1309805299, REVEL 0.27, MetaLR 0.46
- T105H (p.Thr105His), gnomAD X-43711874-GA-G, CADD 25.40
- T105I (p.Thr105Ile), gnomAD X-43711879-C-T, REVEL 0.21, MetaLR 0.52
- T105K (p.Thr105Lys), gnomAD X-43711879-C-A, REVEL 0.27, MetaLR 0.47
- Y106F (p.Tyr106Phe), ESP rs368236433, ExAC rs368236433, TOPMed rs368236433, gnomAD rs368236433, REVEL 0.48, MetaLR 0.64, Uncertain significance, not provided
- Y106Y (p.Tyr106Tyr), rs751569965, gnomAD X-43711883-T-C, CADD 0.56
- P107R (p.Pro107Arg), Ensembl rs1225186530
- P107S (p.Pro107Ser), NCI-TCGA Cosmic COSV1001, MetaLR 0.02, MetaSVM -1.02, Variant assessed as somatic; moderate impact.
- P107T (p.Pro107Thr), ExAC rs755060381, gnomAD rs755060381, REVEL 0.06, MetaLR 0.02
- F108S (p.Phe108Ser), gnomAD X-43711888-T-C, REVEL 0.72, MetaLR 0.79
- R109Q (p.Arg109Gln), rs1039995231, TOPMed rs1039995231, gnomAD rs1039995231, REVEL 0.30, MetaLR 0.52, Variant assessed as somatic; moderate impact.
- R109W (p.Arg109Trp), rs140295792, ClinGen CA10390761, NCI-TCGA Cosmic COSV5864, ClinVar RCV001907529, REVEL 0.47, MetaLR 0.77, Uncertain significance, Inborn genetic diseases; not provided; Brunner syndrome
- R109R (p.Arg109Arg), gnomAD X-43711890-C-A, CADD 8.15
- R109L (p.Arg109Leu), gnomAD X-43711891-G-T, REVEL 0.44, MetaLR 0.62
- G110C (p.Gly110Cys), gnomAD X-43711893-G-T, REVEL 0.84, MetaLR 0.90
- G110G (p.Gly110Gly), rs748344922, gnomAD X-43711895-C-A, CADD 0.14
- A111T (p.Ala111Thr), rs755919316, ClinGen CA10390763, ClinVar RCV003509661, ExAC rs755919316, REVEL 0.14, MetaLR 0.46, Uncertain significance, Brunner syndrome
- A111V (p.Ala111Val), gnomAD X-43711897-C-T, REVEL 0.33, MetaLR 0.60
- F112L (p.Phe112Leu), TOPMed rs2033702607, gnomAD rs2033702607, REVEL 0.15, MetaLR 0.02
- P114Q (p.Pro114Gln), Ensembl rs2033702651, MetaLR 0.87, MetaSVM 0.96
- P114P (p.Pro114Pro), gnomAD X-43711907-A-C, CADD 0.66
- V115I (p.Val115Ile), gnomAD rs1231017846, REVEL 0.04, MetaLR 0.02
- V115L (p.Val115Leu), gnomAD rs1231017846, REVEL 0.07, MetaLR 0.01
- V115V (p.Val115Val), gnomAD X-43711910-A-G, CADD 0.29
- W116* (p.Trp116Ter), NCI-TCGA Cosmic COSV5864, Variant assessed as somatic; high impact.
- W116R (p.Trp116Arg), gnomAD rs1275754919, REVEL 0.70, MetaLR 0.67
- N117Y (p.Asn117Tyr), 1000Genomes rs752534084, ExAC rs752534084, gnomAD rs752534084, REVEL 0.55, MetaLR 0.10
- P118L (p.Pro118Leu), Ensembl rs2033702873
- P118S (p.Pro118Ser), TOPMed rs2033702808, MetaLR 0.89, MetaSVM 0.97
- P118P (p.Pro118Pro), gnomAD X-43711919-C-A, CADD 0.26
- I119N (p.Ile119Asn), NCI-TCGA TCGA novel, MetaLR 0.07, MetaSVM -1.14, Variant assessed as somatic; high impact.
- I119V (p.Ile119Val), rs1252486956, ClinGen CA413004880, ClinVar RCV002817570, gnomAD rs1252486956, REVEL 0.02, MetaLR 0.02, Uncertain significance, Inborn genetic diseases
- A120A (p.Ala120Ala), rs749236767, gnomAD X-43711925-A-G, CADD 1.00
- Y121N (p.Tyr121Asn), gnomAD X-43711926-T-A, REVEL 0.14, MetaLR 0.04
- L122L (p.Leu122Leu), rs998379823, gnomAD X-43711929-T-C, CADD 3.60
- Y124T (p.Tyr124Thr), gnomAD X-43711933-AT-A, CADD 22.60
- Y124C (p.Tyr124Cys), gnomAD X-43711936-A-G, REVEL 0.15, MetaLR 0.03
- Y124* (p.Tyr124Ter), gnomAD X-43711937-C-A, CADD 32.00
- N125S (p.Asn125Ser), rs201799429, ClinGen CA10390766, ClinVar RCV001809165, ExAC rs201799429, REVEL 0.42, MetaLR 0.06, Uncertain significance, Brunner syndrome
- R129K (p.Arg129Lys), ExAC rs745323664, gnomAD rs745323664, REVEL 0.64, MetaLR 0.72
- R129W (p.Arg129Trp), rs1800464, ClinGen CA413004952, ClinVar RCV003159515, 1000Genomes rs1800464, REVEL 0.69, MetaLR 0.72, Uncertain significance, not provided
- R129R (p.Arg129Arg), rs1800464, gnomAD X-43711950-A-C, CADD 4.52
- R129G (p.Arg129Gly), gnomAD X-43711950-A-G, REVEL 0.63, MetaLR 0.80
- T130I (p.Thr130Ile), NCI-TCGA Cosmic COSV5864, MetaLR 0.72, MetaSVM 0.31, Variant assessed as somatic; moderate impact.
- T130T (p.Thr130Thr), gnomAD X-43711955-A-G, CADD 2.77
- I131V (p.Ile131Val), Ensembl rs1569197329, MetaLR 0.64, MetaSVM 0.04, Uncertain significance, Brunner syndrome
- I131M (p.Ile131Met), gnomAD X-43711958-A-G, REVEL 0.31, MetaLR 0.46
- D132H (p.Asp132His), NCI-TCGA TCGA novel, MetaLR 0.14, MetaSVM -0.71, Variant assessed as somatic; moderate impact.
- D132D (p.Asp132Asp), gnomAD X-43711961-T-C, CADD 8.39
- N133K (p.Asn133Lys), Ensembl rs1601940872, MetaLR 0.01, MetaSVM -0.91, Uncertain significance, Inborn genetic diseases
- N133S (p.Asn133Ser), gnomAD X-43711963-A-G, REVEL 0.06, MetaLR 0.02
- M134I (p.Met134Ile), rs771740634, ClinGen CA10390768, ClinVar RCV000692394, ClinVar RCV004985077, AlphaMissense 0.55, MetaLR 0.69, Uncertain significance, Inborn genetic diseases; Brunner syndrome
Public MAOA analysis runs
- MAOA analysis run — MAOA (534 variants) — completed 2026-08-19